Development of a novel azaspirane that targets the Janus Kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo

Journal of Biological Chemistry

Volumn 289, Issue 49, 2014, Pages 34296-34307

  Mohan, Chakrabhavi Dhananjaya ^a   Bharathkumar, Hanumantharayappa ^b   Bulusu, Krishna C ^c   Pandey, Vijay ^d   Rangappa, Shobith ^e   Fuchs, Julian E ^c   Shanmugam, Muthu K ^f   Dai, Xiaoyun ^f   Li, Feng ^f   Deivasigamani, Amudha ^g   Hui, Kam M ^g   Kumar, Alan Prem ^d,g   Lobie, Peter E ^d,g   Bender, Andreas ^c   Basappa, ^b   Sethi, Gautam ^f   Rangappa, Kanchugarakoppal S ^a  

^a UNIVERSITY OF MYSORE   (India)

^b BANGALORE UNIVERSITY   (India)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e HOKKAIDO UNIVERSITY   (Japan)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^g INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CYTOLOGY; DISEASES; GENE THERAPY; MOLECULAR BIOLOGY; PHOSPHORYLATION; TRANSDUCERS; TUMORS;

BIOLOGICAL EVALUATION; DOWN-REGULATION; HEPATOCELLULAR CARCINOMA; NUCLEAR TRANSLOCATIONS; POTENT INHIBITOR; SIGNAL TRANSDUCERS; TUMOR DEVELOPMENT; TUMOR TISSUES;

TRANSCRIPTION;

2 [1 [4 (2 CYANOPHENYL)1 BENZYL 1H INDOL 3 YL] 5 (4 METHOXYPHENYL) 1 OXA 3 AZASPIRO[5,5]UNDECANE]; CASPASE 3; JANUS KINASE 1; JANUS KINASE 2; KI 67 ANTIGEN; MESSENGER RNA; SERINE; SPIRO COMPOUND; STAT3 PROTEIN; TYROSINE; UNCLASSIFIED DRUG; 2-(1-(4-(2-CYANOPHENYL)1-BENZYL-1H-INDOL-3-YL)-5-(4-METHOXY-PHENYL)-1-OXA-3-AZASPIRO(5,5)UNDECANE; ANTINEOPLASTIC AGENT; AZASPIRANE; JAK2 PROTEIN, HUMAN; SMALL INTERFERING RNA; STAT3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL NUCLEUS; CELL PROLIFERATION; CELL VIABILITY; COMPUTER MODEL; CONTROLLED STUDY; DOWN REGULATION; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN TISSUE; IC50; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; LIVER CELL; LIVER NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYNTHESIS; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTES; HUMANS; JANUS KINASE 2; LIVER NEOPLASMS; MICE; MICE, NUDE; PHOSPHORYLATION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SPIRO COMPOUNDS; STAT3 TRANSCRIPTION FACTOR; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84916878743     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.601104     Document Type: Article

References (49)

1. Whang-Peng, J., Cheng, A.-L., Hsu, C., and Chen, C.-M. (2010) Clinical development and future direction for the treatment of hepatocellular carcinoma. J. Exp. Clin. Med. 2, 93-103
2. Rajendran, P., Ong, T. H., Chen, L., Li, F., Shanmugam, M. K., Vali, S., Abbasi, T., Kapoor, S., Sharma, A., Kumar, A. P., Hui, K. M., and Sethi, G. (2011) Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo. Clin. Cancer Res. 17, 1425-1439
3. Sun, B., and Karin, M. (2012) Obesity, inflammation, and liver cancer. J. Hepatol. 56, 704-713
4. Wörns, M. A., and Galle, P. R. (2010) Future perspectives in hepatocellular carcinoma. Dig. Liver Dis. 42, S302-S309
5. Nakagawa, H., and Maeda, S. (2012) Molecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPK. Pathol. Res. Int. 2012, 172894
6. Gish, R. G. (2006) Hepatocellular carcinoma: overcoming challenges in disease management. Clin. Gastroenterol. Hepatol. 4, 252-261
7. McMurray, J. S. (2006) A new small-molecule Stat3 inhibitor. Chem. Biol. 13, 1123-1124
8. Turkson, J., Kim, J. S., Zhang, S., Yuan, J., Huang, M., Glenn, M., Haura, E., Sebti, S., Hamilton, A. D., and Jove, R. (2004) Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol. Cancer Ther. 3, 261-269
9. Frank, D. A. (2007) STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 251, 199-210
10. Huang, S. (2007) Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin. Cancer Res. 13, 1362-1366
11. Bromberg, J. (2002) Stat proteins and oncogenesis. J. Clin. Invest. 109, 1139-1142
12. Temple, C., Jr., Wheeler, G. P., Comber, R. N., Elliott, R. D., and Montgomery, J. A. (1983) Synthesis of potential anticancer agents: pyrido[4, 3-b][1,4]oxazines and pyrido[4,3-b][1,4]thiazines. J. Med. Chem. 26, 1614-1619
13. Basappa, Murugan, S., Kavitha, C. V., Purushothaman, A., Nevin, K. G., Sugahara, K., and Rangappa, K. S. (2010) A small oxazine compound as an anti-tumor agent: a novel pyranoside mimetic that binds to VEGF, HBEGF, and TNF-α. Cancer Lett. 297, 231-243
14. Quintás-Cardama, A., Manshouri, T., Estrov, Z., Harris, D., Zhang, Y., Gaikwad, A., Kantarjian, H. M., and Verstovsek, S. (2011) Preclinical characterization of atiprimod, a novel JAK2 and JAK3 inhibitor. Invest. New Drugs 29, 818-826
15. Yang, S. M., Malaviya, R., Wilson, L. J., Argentieri, R., Chen, X., Yang, C., Wang, B., Cavender, D., and Murray, W. V. (2007) Simplified staurosporine analogs as potent JAK3 inhibitors. Bioorg. Med. Chem. Lett. 17, 326-331
16. Tam, C. S., and Verstovsek, S. (2013) Investigational Janus kinase inhibitors. Expert Opin. Investig. Drugs 22, 687-699
17. Amit-Vazina, M., Shishodia, S., Harris, D., Van, Q., Wang, M., Weber, D., Alexanian, R., Talpaz, M., Aggarwal, B. B., and Estrov, Z. (2005) Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br. J. Cancer 93, 70-80
18. Hamasaki, M., Hideshima, T., Tassone, P., Neri, P., Ishitsuka, K., Yasui, H., Shiraishi, N., Raje, N., Kumar, S., Picker, D. H., Jacob, G. S., Richardson, P. G., Munshi, N. C., and Anderson, K. C. (2005) Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood 105, 4470-4476
19. Wilson, L. J., Malaviya, R., Yang, C., Argentieri, R., Wang, B., Chen, X., Murray, W. V., and Cavender, D. (2009) Synthetic staurosporines via a ring closing metathesis strategy as potent JAK3 inhibitors and modulators of allergic responses. Bioorg. Med. Chem. Lett. 19, 3333-3338
20. Su, Q., Ioannidis, S., Chuaqui, C., Almeida, L., Alimzhanov, M., Bebernitz, G., Bell, K., Block, M., Howard, T., Huang, S., Huszar, D., Read, J. A., Rivard Costa, C., Shi, J., Su, M., Ye, M., and Zinda, M. (2014) Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors. J. Med. Chem. 57, 144-158
21. Furqan, M., Mukhi, N., Lee, B., and Liu, D. (2013) Dysregulation of JAKSTAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark. Res. 1, 5
22. Basappa, Kavitha, C. V., and Rangappa, K. S. (2004) Simple and an efficient method for the synthesis of 1-[2-dimethylamino-1-(4-methoxy-phenyl)-ethyl]-cyclohexanol hydrochloride: (+/-) venlafaxine racemic mixtures. Bioorg. Med. Chem. Lett. 14, 3279-3281
23. Pandey, V., Jung, Y., Kang, J., Steiner, M., Qian, P. X., Banerjee, A., Mitchell, M. D., Wu, Z. S., Zhu, T., Liu, D. X., and Lobie, P. E. (2010) Artemin reduces sensitivity to doxorubicin and paclitaxel in endometrial carcinoma cells through specific regulation of CD24. Transl. Oncol. 3, 218-229
24. Keerthy, H. K., Mohan, C. D., Siveen, K. S., Fuchs, J. E., Rangappa, S., Sundaram, M. S., Li, F., Girish, K. S., Sethi, G., Basappa, Bender, A., and Rangappa, K. S. (2014) Novel synthetic biscoumarins target tumor necrosis factor-α in hepatocellular carcinoma in vitro and in vivo. J. Biol. Chem. 289, 31879-31890
25. Keerthy, H. K., Garg, M., Mohan, C. D., Madan, V., Kanojia, D., Shobith, R., Nanjundaswamy, S., Mason, D. J., Bender, A., Basappa, Rangappa, K. S., and Koeffler, H. P. (2014) Synthesis and characterization of novel 2-amino-chromene-nitriles that target Bcl-2 in acute myeloid leukemia cell lines. PloS One 9, e107118
26. Manu, K. A., Shanmugam, M. K., Ong, T. H., Subramaniam, A., Siveen, K. S., Perumal, E., Samy, R. P., Bist, P., Lim, L. H., Kumar, A. P., Hui, K. M., and Sethi, G. (2013) Emodin suppresses migration and invasion through the modulation of CXCR4 expression in an orthotopic model of human hepatocellular carcinoma. PLoS One 8, e57015
27. Kumar, B., Paricharak, S., Dinesh, K., Siveen, K. S., Fuchs, J., Rangappa, S., Mohan, C. D., Mohandas, N., Kumar, A. P., and Sethi, G. (2014) Synthesis, biological evaluation and in silico and in vitro mode-of-action analysis of novel dihydropyrimidones targeting PPAR-. RSC Adv. 4, 45143-45146
28. Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J. S., Freedman, M., Cohen, A., Gazit, A., Levitzki, A., and Roifman, C. M. (1996) Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379, 645-648
29. Murase, S., and McKay, R. D. (2014) Neuronal activity-dependent STAT3 localization to nucleus is dependent on Tyr-705 and Ser-727 phosphorylation in rat hippocampal neurons. Eur. J. Neurosci. 39, 557-565
30. Decker, T., and Kovarik, P. (2000) Serine phosphorylation of STATs. Oncogene 19, 2628-2637
31. Li, F., Shanmugam, M. K., Chen, L., Chatterjee, S., Basha, J., Kumar, A. P., Kundu, T. K., and Sethi, G. (2013) Garcinol, a polyisoprenylated benzophenone modulates multiple proinflammatory signaling cascades leading to the suppression of growth and survival of head and neck carcinoma. Cancer Prev. Res. 6, 843-854
32. Ihle, J. N. (1996) STATs: signal transducers and activators of transcription. Cell 84, 331-334
33. Schreiner, S. J., Schiavone, A. P., and Smithgall, T. E. (2002) Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. J. Biol. Chem. 277, 45680-45687
34. Rajendran, P., Li, F., Shanmugam, M. K., Kannaiyan, R., Goh, J. N., Wong, K. F., Wang, W., Khin, E., Tergaonkar, V., Kumar, A. P., Luk, J. M., and Sethi, G. (2012) Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo. Cancer Prev. Res. 5, 631-643
35. Yu, C. L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., and Jove, R. (1995) Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269, 81-83
36. Rosmorduc, O., and Desbois-Mouthon, C. (2011) Targeting STAT3 in hepatocellular carcinoma: sorafenib again. J. Hepatol. 55, 957-959
37. Moran, D. M., Mattocks, M. A., Cahill, P. A., Koniaris, L. G., and McKillop, I. H. (2008) Interleukin-6 mediates G0/G1 growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway. J. Surg. Res. 147, 23-33
38. Zauberman, A., Zipori, D., Krupsky, M., and Ben-Levy, R. (1999) Stress activated protein kinase p38 is involved in IL-6 induced transcriptional activation of STAT3. Oncogene 18, 3886-3893
39. Aggarwal, B. B., Vijayalekshmi, R. V., and Sung, B. (2009) Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin. Cancer Res. 15, 425-430
40. Rajendran, P., Li, F., Manu, K. A., Shanmugam, M. K., Loo, S. Y., Kumar, A. P., and Sethi, G. (2011)γ-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent. Br. J. Pharmacol. 163, 283-298
41. Boulares, A. H., Yakovlev, A. G., Ivanova, V., Stoica, B. A., Wang, G., Iyer, S., and Smulson, M. (1999) Role of poly(ADP-ribose) polymerase (PARP) Cleavage in apoptosis: caspase 3-resistant parp mutant increases rates of apoptosis in transfected cells. J. Biol. Chem. 274, 22932-22940
42. Han, Y., Amin, H. M., Franko, B., Frantz, C., Shi, X., and Lai, R. (2006) Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood 108, 2796-2803
43. Koutsoukas, A., Simms, B., Kirchmair, J., Bond, P. J., Whitmore, A. V., Zimmer, S., Young, M. P., Jenkins, J. L., Glick, M., Glen, R. C., and Bender, A. (2011) From in silico target prediction to multi-target drug design: current databases, methods and applications. J. Proteomics 74, 2554-2574
44. Koutsoukas, A., Lowe, R., Kalantarmotamedi, Y., Mussa, H. Y., Klaffke, W., Mitchell, J. B., Glen, R. C., and Bender, A. (2013) In silico target predictions: defining a benchmarking data set and comparison of performance of the multiclass Naive Bayes and Parzen-Rosenblatt window. J. Chem. Inf. Model. 53, 1957-1966
45. Yellaturu, C. R., and Rao, G. N. (2003) Cytosolic phospholipase A2 is an effector of Jak/STAT signaling and is involved in platelet-derived growth factor BB-induced growth in vascular smooth muscle cells. J. Biol. Chem. 278, 9986-9992
46. Hazan-Halevy, I., Harris, D., Liu, Z., Liu, J., Li, P., Chen, X., Shanker, S., Ferrajoli, A., Keating, M. J., and Estrov, Z. (2010) STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood 115, 2852-2863
47. Wen, Z., and Darnell, J. E., Jr. (1997) Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence onDNAbinding of Stat1 and Stat3. Nucleic Acids Res. 25, 2062-2067
48. Nam, S., Wen, W., Schroeder, A., Herrmann, A., Yu, H., Cheng, X., Merz, K. H., Eisenbrand, G., Li, H., Yuan, Y. C., and Jove, R. (2013) Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells. Mol. Oncol. 7, 369-378
49. Gritsko, T., Williams, A., Turkson, J., Kaneko, S., Bowman, T., Huang, M., Nam, S., Eweis, I., Diaz, N., Sullivan, D., Yoder, S., Enkemann, S., Eschrich, S., Lee, J. H., Beam, C. A., Cheng, J., Minton, S., Muro-Cacho, C. A., and Jove, R. (2006) Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. 12, 11-19